FDA Approves Fayuvi for MPS IIIA

Company Ultragenyx Event Type FDA Approval Modality One-Time Intravenous AAV9 Gene Therapy Asset Fayuvi (Rebisufligene Etisparvovec-Hopf, Formerly UX111) Disease Area Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) Summary FDA approved Fayuvi, a one-time intravenous AAV9 gene therapy, for neurologic manifestations of mucopolysaccharidosis IIIA in pediatric…